Physician
Dermatology
Dr. Michael R. Campoli, MD
|
|
Give Review
Michael Campoli practices Dermatology. He went to University at Buffalo, School of Medicine and Biomedical Sciences. He received 1 awards: "CMS Meaningful Use Stage 1 Certification". Michael Campoli is also a published doctor. He has 23 paper published. The most recent paper is: HLA antigen expression in melanocytic lesions: is acquisition of HLA antigen expression a biomarker of atypical (dysplastic) melanocytes? He accepts Medicare payments and is listed with Medicare.gov.
Publications
- HLA antigen expression in melanocytic Lesions: is acquisition of HLA antigen expression a biomarker of atypical (dysplastic) melanocytes?
- Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma Cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical signifi...
- CSPG4 in Cancer: multiple roles.
- Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma Lesions.
- HLA antigen changes in malignant Cells: epigenetic mechanisms and biologic significance.
- Tumor escape mechanisms: potential role of soluble HLA antigens and NK Cells activating ligands.
- Predictors of clinical efficacy of ''Ablate and Pace'' therapy in patients with permanent atrial fibrillation.
- HLA antigen and NK Cell activating ligand expression in malignant Cells: a story of loss or acquisition.
- Functional and clinical relevance of chondroitin sulfate proteoglycan 4.
- Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies.
- Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors.
- Mechanisms of tumor evasion.
- A method to generate antigen-specific mAb capable of staining formalin-fixed, paraffin-embedded tissue sections.
- HLA class I antigen expression in malignant Cells: why does it not always correlate with CTL-mediated lysis?
- T-Cell-based immunotherapy of melanoma: what have we learned and how can we improve?
- HLA class I defects in malignant Lesions: what have we learned?
- HLA class I antigen Loss, tumor immune escape and immune selection.
- Classical and nonclassical HLA class I antigen and NK Cell-activating ligand changes in malignant Cells: current challenges and future directions.
- HLA antigen changes in malignant tumors of mammary epithelial origin: molecular mechanisms and clinical implications.
- Immune selection of hot-spot beta 2-microglobulin gene mutations, HLA-A2 allospecificity Loss, and antigen-processing machinery component down-regulation in melanoma c...
- Immunotherapy of Melanoma targeting human high molecular weight Melanoma-associated antigen: potential role of nonimmunological mechanisms.
- Enhancement of scFv fragment reactivity with target antigens in binding assays following mixing with anti-tag monoclonal antibodies.
Schools
State University of New York At Buffalo
Procedures Preformed
- Adjacent Tissue Transfer
- Destruction of Benign Skin Lesion
- Destruction of Malignant Skin Lesion
- Excision of Benign Skin Lesion
- View All
Conditions Treated
- Acne
- Actinic Keratosis
- Athlete's Foot
- Basal Cell Carcinoma
- View All
Doctors Specialties
- Dermatology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Colorado -
University of Pittsburgh Medical Center -
University at Buffalo, School of Medicine and Biomedical Sciences
Drug Facts
| NPI NUMBER | 1730206541 | |
| NPPES Provider LastName | CAMPOLI | |
| NPPES Provider FirstName | MICHAEL | |
| NPPES Provider ZIPCode | 550928013 | |
| NPPES Provider State | MN | |
| Specialty Description | Dermatology | |
| Total Claim Count | 711.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 43.0 | |
| Percent Opioid Claims | 6.05 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1730206541 |
| Last Name Of The Provider | CAMPOLI |
| First Name Of The Provider | MICHAEL |
| View All |
Similar Doctors
|
|
Dr. Anastasios A. Pappas, MD
 This Doctor is OpenDoctor Recommended.
|